H3D partners with Yemaachi to utilize African genetic diversity to develop new tools for improving treatment outcomes for the African patient populations
H3D has a new collaboration with Yemaachi, a private research company based in Accra, Ghana, that is working towards lowering the economic burden of cancer on the African continent.
Our first joint endeavour is the African Liver Project, which leverages the pharmacology expertise at H3D and the genomics and computational biology capacity at Yemaachi to understand how drug metabolism varies across the continent, with the aim of better optimizing treatment regimens for African populations. Variations in drug metabolism are known to contribute significantly towards adverse drug reactions (ADRs). Africa carries a high burden of ADRs owing partly to the use of poorly-optimized drugs and high levels of genetic diversity. Because of the limited representation of Africans in trials worldwide (2% of clinical trial participants are people of African descent), very little is known about how drugs behave among African populations.
"Due to the paucity of clinical trials in Africa, therapies are not typically optimized for the African patient population, resulting in variable treatment outcomes. Amongst many factors accounting for this is genetic variability in the activity and expression of drug metabolizing enzymes and transporters. This partnership with Yemaachi will ultimately inform patient stratification and dose selection for phase II and III clinical trials for specific existing and new cancer medicines used in Africa.” Prof Kelly Chibale, H3D Director
Please read our official press release here.
Image credit: africanhealthsciences.org